2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy. Gynecologic Oncology Reports 2023, 48: 101219. PMID: 37325293, PMCID: PMC10265462, DOI: 10.1016/j.gore.2023.101219.Peer-Reviewed Original ResearchUterine serous carcinomaHER2/neuSerous carcinomaT-DXdTreatment optionsRecurrent uterine serous carcinomaDose-limiting side effectEffective treatment optionNew treatment optionsBone painRecurrent diseaseDurable responsesTrastuzumab deruxtecanCA 125Disease burdenSide effectsCarcinomaAntibody drugsTreatmentSignificant reductionDiseaseNeuExperimental treatmentsMetastaticPainPembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
McNamara B, Bellone S, Demirkiran C, Hartwich T, Santin A. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy. Gynecologic Oncology Reports 2023, 48: 101218. PMID: 37325296, PMCID: PMC10265468, DOI: 10.1016/j.gore.2023.101218.Peer-Reviewed Original ResearchOvarian clear cell carcinomaClear cell carcinomaCombination of pembrolizumabCell carcinomaTreatment optionsRecurrent ovarian clear cell carcinomaWeeks of therapyCT scan findingsMild side effectsEffective treatment optionOral multikinase inhibitorNew treatment optionsDurable responsesMetastatic diseaseScan findingsPD-1Disease burdenTarget lesionsMultikinase inhibitorDrug combinationsSide effectsPembrolizumabLenvatinibMonoclonal antibodiesCarcinoma
2018
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecologic Oncology Reports 2018, 25: 41-44. PMID: 29946554, PMCID: PMC6014583, DOI: 10.1016/j.gore.2018.05.011.Peer-Reviewed Original ResearchLow-grade serous ovarian carcinomaTreatment optionsHormonal treatmentRecurrent low-grade serous ovarian cancerRecurrent low-grade serous ovarian carcinomaLow-grade serous ovarian cancerDramatic clinical responseDrug-related toxicityEffective treatment optionNew treatment optionsSerial CT scansSerous ovarian cancerSerous ovarian carcinomaMitogen-activated protein kinase inhibitorOral steroidsRECIST 1.1Clinical responseMultiple chemotherapyOvarian carcinomaTarget lesionsOvarian cancerCT scanResponse durationBinimetinibKRAS G12Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD. Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report. Gynecologic Oncology Reports 2018, 25: 37-40. PMID: 29977989, PMCID: PMC6030029, DOI: 10.1016/j.gore.2018.05.009.Peer-Reviewed Original ResearchUterine serous carcinomaSacituzumab govitecanAntibody-drug conjugatesSerous carcinomaTreatment optionsNovel antibody-drug conjugateTreatment-resistant diseaseImpressive clinical responsesSignificant adverse eventsEffective treatment optionNew treatment optionsSerial CT scansUSC patientsAdverse eventsClinical responseMultiple chemotherapyAggressive variantCase reportUterine cancerClinical trialsCT scanDramatic responseSurface antigenTrop-2Chemotherapy